AVIEW LCS vs KardiaAI
AI Verdict
Choose AVIEW LCS if…
Choose AVIEW LCS if your primary need is a comprehensive, AI-powered solution for lung cancer screening and integrated cardiopulmonary assessment from low-dose CT scans. This tool is ideal for radiology departments seeking to automate lung nodule detection, quantify emphysema, and perform coronary artery calcification scoring simultaneously, streamlining diagnostic workflows and enhancing accuracy.
View AVIEW LCS →Choose KardiaAI if…
Choose KardiaAI if you require an FDA-cleared AI software library for the analysis of ambulatory ECG rhythms to detect specific cardiac conditions like AFib, bradycardia, and tachycardia. This tool is best suited for developers or healthcare providers looking to integrate medical-grade heart rhythm analysis capabilities into existing mobile applications, wearable devices, or web platforms for continuous or on-demand patient monitoring.
View KardiaAI →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW LCS | KardiaAI |
|---|---|---|
| Pricing | Subscription or one-off payment | Subscription-based for advanced features and services. |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | Mobile app, cloud-based. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEW LCSAVIEW LCS is designed for seamless integration into existing radiology workflows, including PACS/RIS, and offers automated report generation, which enhances efficiency for radiologists. Its flexible deployment options further contribute to its adaptability within diverse clinical IT environments, making it highly usable for its target professional users.
Clinical Value
AVIEW LCSBoth tools are FDA-cleared and provide significant clinical value in their respective specialties. However, AVIEW LCS offers a broader diagnostic scope by providing integrated, fully automatic analysis for lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan, which can lead to a more comprehensive patient assessment.
Pricing & Value
KardiaAIKardiaAI offers transparent, subscription-based pricing for its KardiaCare services, providing clear value propositions for individual users and small practices. AVIEW LCS, conversely, requires direct contact for pricing, which is typical for enterprise solutions but makes it difficult to assess its comparative value without specific quotes.
Enterprise Readiness
AVIEW LCSBoth tools are FDA-cleared, HIPAA compliant, and offer BAA, indicating strong foundational readiness. AVIEW LCS, however, provides more diverse deployment options (cloud, hybrid, local, virtualized) and explicit integration with core hospital imaging systems like PACS/RIS, making it more adaptable and ready for traditional enterprise healthcare environments.
Innovation
AVIEW LCSAVIEW LCS demonstrates higher innovation by integrating the detection and analysis of three major cardiopulmonary diseasesu2014lung cancer, COPD, and coronary artery calcificationu2014from a single low-dose CT scan. This multi-disease assessment from one imaging modality represents a more novel advancement in diagnostic efficiency and holistic patient care.
Support & Docs
KardiaAIKardiaAI provides extensive and easily accessible support resources, including a dedicated support website with multilingual user manuals, comprehensive FAQs, troubleshooting guides, direct contact information, and an in-app AI assistant. In contrast, readily available and detailed support documentation for AVIEW LCS for end-users is less prominent in public search results.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW LCS | KardiaAI |
|---|---|---|
| Product Name | AVIEW LCS | KardiaAI |
| Company | Coreline Soft Co. | AliveCor |
| Primary Focus | AI-powered solution for detection and analysis of lung nodules, COPD, and coronary artery calcification from CT scans. | FDA-cleared AI software library for analyzing ambulatory ECG rhythms, detecting various cardiac conditions. |
| Categories | Cardiology AI, Oncology AI, Radiology & Imaging AI | Cardiology AI |
| Specialties | Cardiology, Oncology, Pulmonology, Radiology | Cardiology, Emergency Medicine, Internal Medicine |
| Key Features (Examples) | Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Coronary Artery Calcification (CAC) scoring | AI-powered ECG analysis library, Detection of atrial fibrillation, bradycardia, tachycardia, Detection of Sinus Rhythm with Premature Ventricular Contractions (PVCs) |
Videos
Demos, reviews, and walkthroughs featuring AVIEW LCS and KardiaAI.
Frequently Asked Questions
More Comparisons
More matchups featuring AVIEW LCS or KardiaAI
Backers
Who funded each tool's parent company.